Israeli Startup Mitoconix Raises $20M

By the NoCamels team June 27, 2017 < 1 minute

Health News: Suspected Cause Of Huntington's Is Actually A Defense Mechanism That May Lead To New Treatment, Courtesy

June 27, 2017 | Mitoconix Bio, a budding Israeli biopharmaceutical startup focused on therapies for neurological diseases, has secured $20 million in a Series A funding round led by Remiges Ventures. Founded in 2016 at the FutuRx biotechnology incubator, Mitoconix Bio has developed a unique method of slowing neuro-degenerative diseases using drugs which improve mitochondrial functioning. The company has an exclusive license for the technology behind its lead drug, which was developed by founder Daria Mochly-Rosen at Stanford University. The funding will be used to advance Mitoconix’s treatment of Huntington’s disease.